Target intelligence / Profile preview

Constitutive proteasome (cCP)

Target
cCP
Molecular classification
Enzyme, Protease, Multisubunit protease complex
01

Overview

The constitutive proteasome is a major intracellular multi-subunit protease complex responsible for the degradation of misfolded, damaged, and short-lived regulatory proteins via the ubiquitin-proteasome system. It is ubiquitously expressed in almost all eukaryotic cells and consists of a 20S catalytic core particle capped by 19S regulatory particles to form the active 26S proteasome. The catalytic core contains three active subunits—β1 (caspase-like), β2 (trypsin-like), and β5 (chymotryptic-like)—which mediate protein cleavage. In contrast to the immunoproteasome, which is induced during inflammation and expressed in immune cells, the constitutive proteasome maintains baseline cellular proteostasis.

Dysregulation of the constitutive proteasome is heavily implicated in various diseases, particularly hematological malignancies like multiple myeloma and mantle cell lymphoma, where cancer cells rely on high proteasomal activity to survive proteotoxic stress. It is also linked to neurodegenerative diseases, where its function declines, leading to toxic protein aggregation. Clinically, the constitutive proteasome is a highly validated therapeutic target. FDA-approved proteasome inhibitors, such as bortezomib, carfilzomib, and ixazomib, primarily target the β5 chymotryptic subunit, inducing severe endoplasmic reticulum stress, unfolded protein response, and apoptosis in cancer cells. However, systemic inhibition of this ubiquitous complex is associated with significant toxicities, such as peripheral neuropathy and myelosuppression, prompting the development of more selective inhibitors.

Other names
Standard proteasomec-20S20S constitutive proteasome26S constitutive proteasomeConstitutive 20S proteasome core particle
02

Mechanism of action

Inhibition of the chymotrypsin-like activity of the beta5 subunit of the 20S core particle, leading to accumulation of ubiquitinated proteins, endoplasmic reticulum stress, and apoptosis.

03

Biological functions

Protein degradationProtein homeostasisApoptosisCell cycle regulationAntigen presentationUnfolded protein response
04

Disease associations

CancerNeurodegenerative diseaseInflammationAutoimmune disease
05

Safety considerations

Peripheral neuropathyMyelosuppressionGastrointestinal toxicityCardiotoxicitySystemic toxicityDrug resistance
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Chymotrypsin-like activityImmunoproteasome to constitutive proteasome ratioTJP1 expressionMIF expressionSOD1 expression

Beyond the preview

Go deeper on Constitutive proteasome (cCP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Constitutive proteasome (cCP).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call